Top News
NRG1 Fusions Identified Across Solid Tumor Types
No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival
FDA Approves New First-Line Treatment for Advanced RCC
AGA Clinical Practice Update: DAAs for Hepatitis C and Hepatocellular Cancer
CDC: Recent Decline Seen in High-Grade Cervical Lesions
Checklist Ensures Adherence to Recommended CAR-T Cell Administration Processes
Linking EHR and Genomic Data to Evaluate Patterns of Care
AFP SPEAR T-Cells Deemed Safe in First 2 Treated Patients With Hepatocellular Carcinoma
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Wider Use of Basket Trials Could Hasten Development of Precision Therapies
Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration. -
AR-V7 Positivity May Inform Treatment Decisions for mCRPC
Men with aggressive prostate cancer who test positive for AR-V7 in circulating tumors cells are unlikely to benefit from treatment with abiraterone or enzalutamide. -
Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts. -
Claims-Based Survival Models Have Potential to Aid Prostate Cancer Decision Making
“Most men with early-stage prostate cancer will die with their disease, not from their disease,” Dr Murphy said. -
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients. -
Immunosuppression Tied to Poor Outcomes in Multiple Cutaneous SCC
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
More Features
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen.
Nivolumab Plus Ipilimumab Proven Cost Effective in Advanced RCC
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
The Hidden Privilege of Reference Genomes
Researchers establish a Chinese-specific BRCA database to cover nearly all of the BRCA variation information currently known across this population.
Digital Issue
